Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis

Pediatric Infectious Disease Journal

Volumn 22, Issue 5, 2003, Pages 434-438

  Sundar, Shyam ^a   Jha, T K ^b   Sindermann, Herbert ^c   Junge, Klaus ^c   Bachmann, Peter ^c   Berman, Jonathan ^d  

^a BANARAS HINDU UNIVERSITY   (India)

^b Kala azar Research Center   (India)

^c ASTA MEDICA AG   (Germany)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Children; Efficacy; Miltefosine; Oral treatment; Toxicity; Visceral leishmaniasis

Indexed keywords

MILTEFOSINE;

ANOREXIA; ARTICLE; ASPIRATION BIOPSY; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; EYE TOXICITY; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; INDIA; LIVER TOXICITY; NAUSEA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RELAPSE; SPLEEN BIOPSY; SPLENOMEGALY; TREATMENT FAILURE; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS; VOMITING;

EID: 0037910173     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000066877.72624.cb     Document Type: Article

References (10)

1. Bora D. Epidemiology of visceral leishmaniasis in India. Nat Med J India 1999;12:62-7.
2. Sundar S, More D, Singh MK, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000;31:1104-7.
3. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 2001;6:849-54.
4. Sundar S, Rosenkaimer F, Makharia MK, et al. Trial of oral miltefosine treatment for visceral leishmaniasis. Lancet 1998;352:1821-4.
5. Sundar S, Gupta LB, Makharia MK, et al. Oral treatment of visceral leishmaniasis with miltefosine. Ann Trop Med Parasitol 1999;93:589-97.
6. Jha TK, Sundar S, Thakur CP, et al. Miltefosine, an oral agent for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999;341:1795-800.
7. Sundar S, Makharia A, DK More DK, et al. Short-course oral miltefosine treatment for visceral leishmaniasis. Clin Infect Dis 2000;31:1110-3.
8. Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002;347:1739-46.
9. Chulay, JD, Bryceson AD. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg 1983;32:475-9.
10. Knebel NG, Grieb S, Winkler M, Locher M, van der Vlis E, Verheij ER. Quantification of perifosine, an alkylphosphocholine anti-tumour agent in plasma by pneumatically assisted electrospray-tandem mass spectrometry coupled with highperformance liquid chromatography. J Chromatogr B Biomed Sci Appl 1999;721:257-69.